Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...